Clinical Trial: Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444632) titled 'Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies' on Feb. 26.

Brief Summary: This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.

Study Start Date: Aug. 31, 2026

Study Type: INTERVENTIONAL

Condition: Lymphoid Hodgkin Lymphoma

Intervention: DRUG: Rituximab

Given by IV

DRUG: Fludarabine

Given by IV

DRUG: TGFBR2 KO CAR27/IL-15 NK cells

Given by IV

DRUG: Cyclophosphamide

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Spon...